Analysts Set Expectations for Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at Chardan Capital issued their FY2025 earnings estimates for Ocugen in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will post earnings of ($0.25) per share for the year. Chardan Capital has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Ocugen in a research note on Thursday, March 6th.

Ocugen Stock Performance

NASDAQ:OCGN opened at $0.72 on Thursday. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. Ocugen has a twelve month low of $0.52 and a twelve month high of $2.08. The company has a fifty day moving average of $0.67 and a 200-day moving average of $0.84. The firm has a market capitalization of $211.39 million, a P/E ratio of -4.02 and a beta of 3.88.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. During the same period in the previous year, the business earned ($0.03) EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in Ocugen in the 3rd quarter valued at about $93,000. MetLife Investment Management LLC raised its stake in shares of Ocugen by 36.4% in the third quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock worth $89,000 after purchasing an additional 23,877 shares during the last quarter. State Street Corp lifted its holdings in shares of Ocugen by 7.1% in the third quarter. State Street Corp now owns 15,824,517 shares of the company’s stock valued at $15,701,000 after purchasing an additional 1,047,896 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Ocugen during the third quarter valued at approximately $456,000. Finally, XTX Topco Ltd bought a new stake in Ocugen during the third quarter worth $233,000. 10.27% of the stock is owned by institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.